BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 15025739)

  • 1. Population pharmacokinetics of raltitrexed in patients with advanced solid tumours.
    Blair EY; Rivory LP; Clarke SJ; McLachlan AJ
    Br J Clin Pharmacol; 2004 Apr; 57(4):416-26. PubMed ID: 15025739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic evaluation of the vinorelbine-lapatinib combination in the treatment of breast cancer patients.
    Rezai K; Urien S; Isambert N; Roche H; Dieras V; Berille J; Bonneterre J; Brain E; Lokiec F
    Cancer Chemother Pharmacol; 2011 Dec; 68(6):1529-36. PubMed ID: 21519841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic analysis of ten phase II clinical trials of pemetrexed in cancer patients.
    Latz JE; Chaudhary A; Ghosh A; Johnson RD
    Cancer Chemother Pharmacol; 2006 Apr; 57(4):401-11. PubMed ID: 16322991
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma.
    Colom H; Farré R; Soy D; Peraire C; Cendros JM; Pardo N; Torrent M; Domenech J; Mangues MA
    Ther Drug Monit; 2009 Feb; 31(1):76-85. PubMed ID: 19077931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High dose methotrexate population pharmacokinetics and Bayesian estimation in patients with lymphoid malignancy.
    Min Y; Qiang F; Peng L; Zhu Z
    Biopharm Drug Dispos; 2009 Nov; 30(8):437-47. PubMed ID: 19746402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase I study of raltitrexed, an antifolate thymidylate synthase inhibitor, in adult patients with advanced solid tumors.
    Grem JL; Sorensen JM; Cullen E; Takimoto CH; Steinberg SM; Chen AP; Hamilton JM; Arbuck SG; McAtee N; Lawrence D; Goldspiel B; Johnston PG; Allegra CJ
    Clin Cancer Res; 1999 Sep; 5(9):2381-91. PubMed ID: 10499608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies.
    Mougenot P; Pinguet F; Fabbro M; Culine S; Poujol S; Astre C; Bressolle F
    Cancer Chemother Pharmacol; 2004 Jun; 53(6):503-12. PubMed ID: 15007638
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study.
    Horton TM; Blaney SM; Langevin AM; Kuhn J; Kamen B; Berg SL; Bernstein M; Weitman S
    Clin Cancer Res; 2005 Mar; 11(5):1884-9. PubMed ID: 15756014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data.
    Fukuhara K; Ikawa K; Morikawa N; Kumagai K
    J Clin Pharm Ther; 2008 Dec; 33(6):677-84. PubMed ID: 19138246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetic study of methotrexate in patients with lymphoid malignancy.
    Faltaos DW; Hulot JS; Urien S; Morel V; Kaloshi G; Fernandez C; Xuan kH; Leblond V; Lechat P
    Cancer Chemother Pharmacol; 2006 Nov; 58(5):626-33. PubMed ID: 16528531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%.
    Knibbe CA; Zuideveld KP; DeJongh J; Kuks PF; Aarts LP; Danhof M
    Clin Pharmacol Ther; 2002 Dec; 72(6):670-84. PubMed ID: 12496748
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of APOMINE: a meta-analysis in cancer patients and healthy males.
    Bonate PL; Floret S; Bentzen C
    Br J Clin Pharmacol; 2004 Aug; 58(2):142-55. PubMed ID: 15255796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
    Joerger M; Huitema AD; Meenhorst PL; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2005 May; 55(5):488-96. PubMed ID: 15726371
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of two population pharmacokinetic programs, NONMEM and P-PHARM, for tacrolimus.
    Staatz CE; Tett SE
    Eur J Clin Pharmacol; 2002 Dec; 58(9):597-605. PubMed ID: 12483452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.